Regencell Bioscience Holdings Ltd（RGC）股票分析

$9.590

+0.071 (+0.74%)收盘时

Loading chart…

最高: 10.330
开盘: 10.305
成交量加权均价: 9.58
成交量: 688.21K
市值: 45.81M
最低: 8.830
成交额: 6.60M
企业价值/息税折旧摊销前利润（TTM）: 0.00

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

www.regencellbioscience.com

AI 分析 of Regencell Bioscience Holdings Ltd (RGC)

买入

Regencell Bioscience Holdings Ltd is a good buy right now due to its recent strong performance, with a 5-day change of +30.48% and a significant increase in trading volume at 688,207 shares, which is 2.44 times the 20-day average. However, the stock has a high RSI of 86.065, indicating it may be overbought in the short term, presenting a risk if the momentum reverses.

分析师评级（15）

买入

9 买入

5 持有

1 卖出

当前: 9.59

最低

—

平均

—

最高

—

查看全部评级

估值指标

Regencell Bioscience Holdings Ltd（RGC）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。

预期市盈率

严重低估

5 年均值 P/E

0.00

当前P/E

0.00

高估

0.00

低估

0.00

预期 EV/EBITDA

严重低估

5 年均值 EV/EBITDA

0.00

当前EV/EBITDA

0.00

高估

0.00

低估

0.00

预期市销率

严重低估

5 年均值 P/S

0.00

当前P/S

0.00

高估

0.00

低估

0.00

Alphio AI 对 RGC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%RGC

$19.32

情景价格

基

基准

基准 · 50%RGC

$17.51

情景价格

悲

悲观

悲观 · 25%RGC

$15.37

情景价格

事件时间线

2026-10-15 (ET)

12:30:00

Regencell Bioscience Shares Rise 11.7% to $9.06

2026-10-14 (ET)

10:30:00

Regencell Bioscience Stock Rises 8.4% to $8.88

2026-10-13 (ET)

12:30:00

Regencell Bioscience Shares Rise 9% to $7.77

2026-10-08 (ET)

12:30:00

Regencell Bioscience Stock Rises 9.1% to $7.76

2026-07-08 (ET)

12:30:00

Regencell Bioscience Stock Rises 25.2% to $7.45

查看更多事件

资讯

查看更多资讯

RGC 常见问题 —— 由 Alphio AI 解答

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

Regencell Bioscience Holdings Ltd is a good buy right now due to its recent strong performance, with a 5-day change of +30.48% and a significant increase in trading volume at 688,207 shares, which is 2.44 times the 20-day average. However, the stock has a high RSI of 86.065, indicating it may be overbought in the short term, presenting a risk if the momentum reverses.

15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.

社区

分享你对 RGC 的看法

暂无帖子

注册或登录后参与讨论

本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。